Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease
Nephrology Dialysis Transplantation · 05.02.2025 · 40 (Supplement_1) · i59-i69
DOI: 10.1093/ndt/gfae258 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 05.02.2025. Verfasst von Brendon L Neuen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Diabetic Nephropathies, Standard of Care, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer AG.
Abstract (Originalsprache)
PLAIN ENGLISH SUMMARY Combination therapy, involving the use of multiple medications together, is becoming a new standard of care for chronic kidney disease (CKD). For people with CKD, combination therapy offers the promise of preventing kidney failure and reducing the risk of heart problems. This approach is appealing because different drugs target distinct mechanisms involved in CKD progression. For instance, some target immune responses, others reduce kidney inflammation and scarring, while others improve blood pressure within the kidneys. Data from large clinical trials suggest that each treatment works effectively on its own, regardless of other medications people are taking. Combining therapies can also reduce the risk of side effects of individual medications. This review highlights the evidence for combination therapy in CKD, explores how to improve its use, and discusses how future studies may answer remaining questions. ABSTRACT A range of therapies now exists to reduce the risk of kidney failure and cardiovascular events in people with type 2 diabetes, including renin–angiotensin system blockade, sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists. With multiple clinical trials underway, it is likely that at least some of these therapies—as well as additional agents such as endothelin receptor antagonists—will further demonstrate kidney-protective effects in people with CKD who do not have diabetes in the near future. For conditions such as IgA nephropathy, several therapies have recently been approved or are being evaluated in late phase trials. Thus combination therapy is emerging as a new standard for diabetic and non-diabetic chronic kidney disease (CKD). This approach is supported by randomized data suggesting that each therapeutic class offers independent and additive benefits in diabetic kidney disease, regardless of background therapy. Notably, the reduction in hyperkalaemia and fluid retention with SGLT2 inhibitors may enhance the tolerability and safety of other treatments. In this review, we present the rationale for combination therapy with evidence-based kidney therapies in diabetic and non-diabetic CKD. We also summarize randomized evidence supporting a multi-medicine approach, address safety considerations, review ongoing trials, and propose frameworks for implementing treatments aligned with patient risk to optimize person-centred care and reduce long-term risks of kidney failure and related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.
- Department of Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- George Washington University School of Medicine, Washington DC, USA.
- Washington DC VA Medical Center, Washington DC, USA.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
ORCID-Profile: Brendon L Neuen, Muthiah Vaduganathan
Förderung
- Bayer AG
Zitieren
APA
Neuen, B. L., Yeung, E. K., Rangaswami, J., & Vaduganathan, M. (2025). Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrology Dialysis Transplantation, 40(Supplement_1), i59-i69. https://doi.org/10.1093/ndt/gfae258
Vancouver
Neuen BL, Yeung EK, Rangaswami J, Vaduganathan M. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrology Dialysis Transplantation. 2025;40(Supplement_1):i59-i69. doi:10.1093/ndt/gfae258
BibTeX
@article{Neuen2025,
author = {Neuen, Brendon L and Yeung, Emily K and Rangaswami, Janani and Vaduganathan, Muthiah},
title = {Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {Supplement_1},
pages = {i59--i69},
doi = {10.1093/ndt/gfae258}
}
EUVIMED